TacticScaleWhat Teleflex Does & How It Makes Money (TFX)
Updated October 2026 · reflects Teleflex's latest reported financials
Maker of single-use medical devices for critical care and surgery. It earns revenue by manufacturing and selling single-use devices to hospitals, healthcare providers and other medical device manufacturers, including through online sales.
How Teleflex makes money
It earns revenue by manufacturing and selling single-use devices to hospitals, healthcare providers and other medical device manufacturers, including through online sales. Because the products are disposable and used in routine procedures, hospitals keep buying them.
What Teleflex does
Teleflex Incorporated, founded in 1943 and headquartered in Wayne, Pennsylvania, designs and makes single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgery. Its vascular and emergency medicine line includes Arrow catheters, catheter navigation and tip positioning systems, EZ-IO and Arrow FAST1 intraosseous access systems, and QuikClot hemostatic and trauma products. Its interventional business sells coronary and peripheral catheters such as GuideLiner, Turnpike and TrapLiner, structural heart support devices, MANTA vascular closure devices, the Arrow OnControl powered bone biopsy system, drug-coated balloons and stents. Its surgical portfolio covers ligating clips, laparoscopic fascial closure systems, percutaneous surgical systems and powered bariatric staplers, sold under brands including Weck, Pleur-Evac, Deknatel, KMedic, Pilling and Titan SGS. Teleflex sells to hospitals, healthcare providers and medical device manufacturers in the U.S., Europe, the Middle East, Africa and Asia Pacific.
Products & services
- Arrow catheters and EZ-IO intraosseous access systems
- QuikClot hemostatic products
- GuideLiner, Turnpike and TrapLiner catheters
- MANTA vascular closure devices
- Weck ligating clips and surgical instruments
- Titan SGS powered bariatric staplers
What is Teleflex worth?
On an owner-earnings DCF, Teleflex's most-likely value is about $150 versus a recent price near $125 (20% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$86) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
⚠ High leverage — net debt is 7.6× annual cash flow. Net debt is subtracted from this fair value, but refinancing at higher rates, principal timing, and share dilution aren’t modeled — the equity can be worth far less if cash flow weakens.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Merit Medical Systems (MMSI) · Medtronic (MDT) · Baxter International (BAX) · Becton, Dickinson and (BDX) · Fortive (FTV)